James Edgemond, who serves as Chief Financial Officer and Treasurer at United Therapeutics (NASDAQ: UTHR), completed a series of stock sales on April 6, 2026, disposing of 7,351 shares of common stock for an aggregate amount of roughly $5.58 million. The sales were carried out in multiple transactions with execution prices ranging from $552.7801 to $566.01 per share.
On the same date, Edgemond also exercised stock options to acquire an additional 10,000 shares of United Therapeutics common stock at an exercise price of $135.42 per share, representing a total outlay of $1,354,199.
Following these two sets of transactions, Edgemond directly holds 18,876 shares of United Therapeutics. At current market prices, that stake is valued at approximately $10.7 million.
The timing of the insider activity coincides with United Therapeutics shares trading close to a 52-week high of $607.89, after the stock delivered a 92% return over the past year. According to InvestingPro analysis cited in reports on the stock, United Therapeutics appears overvalued relative to its Fair Value and is listed among names on the Most Overvalued list. Investors interested in deeper valuation and research materials are pointed to a Pro Research Report available for UTHR and more than 1,400 other U.S. equities.
These moves by the company CFO follow recent clinical and market developments tied to United Therapeutics. The company announced Phase 3 TETON-1 trial results for Tyvaso, its candidate aimed at treating idiopathic pulmonary fibrosis - commonly referred to as IPF. Market participants and sell-side analysts responded to the trial outcomes with updated views and price targets.
H.C. Wainwright raised its price target for United Therapeutics to $660 and maintained a Buy rating, citing the strength of the TETON-1 data in supporting potential expansion of Tyvaso in IPF. Bank of America Securities increased its price target to $626 from $569 while retaining a Neutral rating, describing the TETON-1 data as a second confirmatory trial for the drug. Jefferies also lifted its price target to $733 from $668 and kept a Buy rating, noting that the trial results beat expectations. Jefferies additionally increased its modeled probability of success for Tyvaso to 95% in IPF and to 70% in progressive pulmonary fibrosis.
Market ripple effects were visible across the pulmonary and biotech space. The reporting noted that Insmed's stock rose after Morgan Stanley upgraded the company to Overweight, with that move described as being partly influenced by the positive data from United Therapeutics.
The combination of insider selling, option exercise, elevated share prices, and analyst revisions presents multiple data points for market observers to consider. The transactions are recorded as factual events, while market commentary and valuation assessments reflect third-party analysis made public alongside the clinical trial news.
Key developments at a glance
- Edgemond sold 7,351 shares on April 6, 2026, for approximately $5.58 million, with sale prices between $552.7801 and $566.01 per share.
- He exercised options to buy 10,000 shares at $135.42, paying $1,354,199 in total on the same day.
- After transactions, his direct holdings stand at 18,876 shares, valued around $10.7 million at current market prices.